PEPID Pulse
  • Blog
  • Alerts
  • Press
  • pepid.com
Select Page
FDA Approves New Treatment for HSDD in Premenopausal Women

FDA Approves New Treatment for HSDD in Premenopausal Women

by PEPID Newsroom | Jun 21, 2019 | Alerts

FDA approves bremelanotide  (Vyleesi, AMAG Pharmaceuticals) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide is the first-in-class melanocortin 4 receptor agonist for HSDD, and joins Flibanserin as...

Recent Posts

  • Men’s Health Month – Closing Gaps in Prevention and Early Detection
  • Beyond the Beach – Occupational Skin Cancer Risks in Outdoor Workers
  • Tackling Antimicrobial Resistance: How to fight back against the rise in tough cases
  • The ‘Forever Chemicals’ Crisis: What Healthcare Providers Need to Know About PFAS
  • Top Challenges Faced by Emergency Medicine Residents and How to Overcome Them

Categories

  • Alerts
  • Emergency Medicine
  • Featured Posts
  • Nursing
  • Pharmacy
  • Press & Media
  • Primary Care
  • Uncategorized
PEPID, LLC. All rights reserved